You are here: Home » News-IANS » Health-Medicine

Novel fungus-fighting compound found

Researchers have identified a compound that blocks the growth of a fungus that causes deadly lung infections and allergic reactions in people with compromised immune systems.

The research team targetted the mechanism that allows the fungus Aspergillus fumigatus to survive in iron-deficient conditions like the human body.

Specifically, they targetted an enzyme known as SidA, which is essential for the synthesis of molecules called siderophores that are made during infection to steal iron from human proteins.

Furthermore, by performing high-throughput screening in the Virginia Tech Center for Drug Discovery Screening Laboratory, they found a compound called Celastrol that blocks the growth of iron-producing organelles in the fungus.

"The discovery of Celastrol as a SidA inhibitor represents the first building block in the development of drugs against A. fumigatus and related pathogens," said Julia Martin del Campo, a postdoctoral research scientist at Virginia Tech in the US.

Aspergillus fumigatus is common and is typically found in soil and decaying organic matter.

Most people are exposed to it daily with little consequence, but it can cause lung damage in people with compromised immune systems, such as organ transplant recipients and people with AIDS or leukemia.

The mortality rate of this population, when exposed to the fungus, is more than 50 per cent, according to the authors.

The results were published in the journal ACS Chemical Biology.

--IANS

gb/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22
Business Standard

Novel fungus-fighting compound found

IANS  |  New York 

Researchers have identified a compound that blocks the growth of a fungus that causes deadly lung infections and allergic reactions in people with compromised immune systems.

The research team targetted the mechanism that allows the fungus Aspergillus fumigatus to survive in iron-deficient conditions like the human body.

Specifically, they targetted an enzyme known as SidA, which is essential for the synthesis of molecules called siderophores that are made during infection to steal iron from human proteins.

Furthermore, by performing high-throughput screening in the Virginia Tech Center for Drug Discovery Screening Laboratory, they found a compound called Celastrol that blocks the growth of iron-producing organelles in the fungus.

"The discovery of Celastrol as a SidA inhibitor represents the first building block in the development of drugs against A. fumigatus and related pathogens," said Julia Martin del Campo, a postdoctoral research scientist at Virginia Tech in the US.

Aspergillus fumigatus is common and is typically found in soil and decaying organic matter.

Most people are exposed to it daily with little consequence, but it can cause lung damage in people with compromised immune systems, such as organ transplant recipients and people with AIDS or leukemia.

The mortality rate of this population, when exposed to the fungus, is more than 50 per cent, according to the authors.

The results were published in the journal ACS Chemical Biology.

--IANS

gb/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Novel fungus-fighting compound found

Researchers have identified a compound that blocks the growth of a fungus that causes deadly lung infections and allergic reactions in people with compromised immune systems.

Researchers have identified a compound that blocks the growth of a fungus that causes deadly lung infections and allergic reactions in people with compromised immune systems.

The research team targetted the mechanism that allows the fungus Aspergillus fumigatus to survive in iron-deficient conditions like the human body.

Specifically, they targetted an enzyme known as SidA, which is essential for the synthesis of molecules called siderophores that are made during infection to steal iron from human proteins.

Furthermore, by performing high-throughput screening in the Virginia Tech Center for Drug Discovery Screening Laboratory, they found a compound called Celastrol that blocks the growth of iron-producing organelles in the fungus.

"The discovery of Celastrol as a SidA inhibitor represents the first building block in the development of drugs against A. fumigatus and related pathogens," said Julia Martin del Campo, a postdoctoral research scientist at Virginia Tech in the US.

Aspergillus fumigatus is common and is typically found in soil and decaying organic matter.

Most people are exposed to it daily with little consequence, but it can cause lung damage in people with compromised immune systems, such as organ transplant recipients and people with AIDS or leukemia.

The mortality rate of this population, when exposed to the fungus, is more than 50 per cent, according to the authors.

The results were published in the journal ACS Chemical Biology.

--IANS

gb/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard